second generation anti-claudin 18.2 antibodies (Ganymed Pharmaceuticals)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namesecond generation anti-claudin 18.2 antibodies (Ganymed Pharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionClaudin 18 protein modulators
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGanymed Pharmaceuticals AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGanymed Pharmaceuticals AG
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A